Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 8/20 | 0.64 |
| ▸ | TLK2 | Q86UE8 | 4/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | PAK4 | O96013 | 7/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | NEK2 | P51955 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8588052 | 0.82 | MAP4K1 (0.44) | PDPK1TLK2NTRK1PDGFRBPDGFRA | |
| SCHEMBL8588039 | 0.82 | MAP4K1 (0.44) | PDPK1TLK2NTRK1PDGFRBPDGFRA | |
| SCHEMBL8529701 | 0.80 | KDM4E (0.47) | NTRK1PDGFRBKDRRETFLT3 | |
| SCHEMBL5369374 | 0.80 | TLK2 (0.71) | PDPK1TLK2NTRK1PDGFRBPDGFRA | |
| SCHEMBL8586259 | 0.79 | NTRK1 (0.57) | PDPK1NTRK1PDGFRBPDGFRAKDR | |
| SCHEMBL8586257 | 0.79 | NTRK1 (0.57) | PDPK1NTRK1PDGFRBPDGFRAKDR | |
| SCHEMBL5367043 | 0.79 | NTRK1 (0.66) | PDPK1TLK2NTRK1JAK3CDK1 | |
| SCHEMBL5728024 | 0.79 | TLK2 (1.00) | PDPK1TLK2NTRK1PDGFRBPDGFRA | |
| SCHEMBL5728025 | 0.79 | TLK2 (1.00) | PDPK1TLK2NTRK1PDGFRBPDGFRA | |
| SCHEMBL5364426 | 0.78 | RET (0.67) | PDPK1TLK2NTRK1PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1247803-A2 | Indolinone compounds suitable for modulation of protein kinases | Sugen, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PDPK1 31/4885TLK2 48/4885NTRK1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.